U.S. Markets closed
  • S&P 500

    4,551.68
    -23.11 (-0.51%)
     
  • Dow 30

    35,490.69
    -266.19 (-0.74%)
     
  • Nasdaq

    15,235.84
    +0.12 (+0.00%)
     
  • Russell 2000

    2,252.49
    -43.58 (-1.90%)
     
  • Gold

    1,798.30
    +4.90 (+0.27%)
     
  • EUR/USD

    1.1608
    +0.0005 (+0.0464%)
     
  • 10-Yr Bond

    1.5290
    -0.0900 (-5.56%)
     
  • Vix

    16.98
    +1.00 (+6.26%)
     
  • GBP/USD

    1.3742
    -0.0021 (-0.1553%)
     
  • USD/JPY

    113.8240
    -0.3050 (-0.2672%)
     
  • BTC-USD

    58,903.39
    -3,080.61 (-4.97%)
     
  • CMC Crypto 200

    1,406.02
    -68.31 (-4.63%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • Nikkei 225

    29,098.24
    -7.76 (-0.03%)
     

Why Immunic's Stock Is Trading Higher Today

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Immunic (NASDAQ: IMUX) shares are trading higher on Friday after SVB Leerink initiated coverage on the stock with an Outperform rating and announced a price target of $45 per share.

Immunic is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORγt and IMU-856 targets the restoration of the intestinal barrier function.

Immunic shares traded up 8.43% to $20.46 on Friday. The stock has a 52-week high of $23.39 and a 52-week low of $4.19.

Latest Ratings for IMUX

Oct 2020

SVB Leerink

Initiates Coverage On

Outperform

Aug 2020

Piper Sandler

Initiates Coverage On

Overweight

Aug 2020

HC Wainwright & Co.

Maintains

Buy

View More Analyst Ratings for IMUX
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.